Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions
15 September 2020 - 9:05PM
Business Wire
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a
clinical-stage biopharmaceutical company focused on rare
hematologic diseases and cancers, today announced the appointments
of Fitzroy Dawkins, M.D., as vice president, clinical development
and Ruth du Moulin, Ph.D., as vice president, medical affairs.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200915005321/en/
Fitzroy Dawkins, M.D. (Photo: Business
Wire)
“I am very pleased to welcome our new colleagues to the team,”
said Frank Lee, president and chief executive officer of Forma.
“Fitzroy will be integral to the implementation and execution of
our global pivotal Phase 2/3 trial of FT-4202, a potentially
foundational, disease-modifying therapy for people living with
sickle cell disease (SCD) expected to initiate in the first half of
2021, as well as in leading our development team evaluating Forma’s
CBP/p300 inhibitor for the treatment of metastatic
castration-resistant prostate cancer. Ruth is an essential hire for
Forma as well. Her comprehensive skillset and broad therapeutic
experience position her well to lead a medical affairs team focused
on strategic engagement with the medical community, delivering
impactful medical communications and ensuring our real-world
evidence-generation plans address the needs of our target patient
groups.”
Dr. Dawkins, a hematologist/oncologist, brings more than 12
years of experience in academia and more than 14 years in drug
development. He most recently served as executive director,
oncology drug development at Incyte Corporation where he led
numerous clinical trials in hematologic diseases and cancers,
including an investigational therapeutic for patients with SCD. Dr.
Dawkins earned a Bachelor of Science degree in biology from York
College of the City University of New York and a medical degree
from SUNY-Buffalo.
Dr. du Moulin joins Forma from Takeda Oncology Global Business
Unit where she served as vice president, medical affairs and head
of global oncology medical communications. She has more than 15
years of experience building medical affairs departments and
functions, setting medical affairs strategy and executing
successful product launches in rare disease settings. Dr. du Moulin
earned her Ph.D. in biochemistry at the National University of
Ireland, Galway (NUI-G), Ireland, followed by post-doctorate
research at the Heart Research Institute (HRI) in Sydney,
Australia.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company
focused on the research, development and commercialization of novel
therapeutics to transform the lives of patients with rare
hematologic diseases and cancers. Our R&D engine combines deep
biology insight, chemistry expertise and clinical development
capabilities to create drug candidates with differentiated
mechanisms of action focused on indications with high unmet need.
Our work has generated a broad proprietary portfolio of programs
with the potential to provide profound patient benefit. For more
information, please visit www.FormaTherapeutics.com or follow us on
Twitter @FORMAInc and LinkedIn.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, express or implied
statements regarding the advancement of our sickle cell disease
program, our expectations of the therapeutic benefits related
thereto, the timing and success of ongoing clinical trials, and our
growth as a company and the anticipated contribution of our
executives and employees to our operations and progress.. The words
“may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs and are subject to
a number of risks, uncertainties and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation, those risks and
uncertainties related to the advancement of our clinical programs
and other risks identified in our SEC filings, including those
risks discussed under the heading “Risk Factors” in our Quarterly
Report on Form 10-Q for the quarter ended June 30, 2020, as well as
other risks detailed in our subsequent filings with the SEC. We
caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made. We
disclaim any obligation to publicly update or revise any such
statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200915005321/en/
Media Contact: Kari Watson, +1 781-235-3060 MacDougall
kwatson@macbiocom.com
Investor Contact: Stephanie Ascher, +1 212-362-1200 Stern
Investor Relations stephanie.ascher@sternir.com
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024